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ILUVIEN for Diabetic Macular Edema (Alimera Sciences) 
DME 
• Affects 1m in US 
• Leading cause of vision loss in people under 65 
• Laser therapy (burns to retina) limited efficacy 
• No FDA approved drug treatments 
• US Market estimated $1.5-4B 
Iluvien Status 
• Phase III clinical trials in approx. 1,000 patients 
• NDA given Priority Review 
• Received CRL December 2010 
• Positive 36 month data released in Feb, subgroup analysis in May 
• Resubmitted May 2011  
• Potential approval in Q4 2011 
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Efficacy in Patients with Chronic DME 




ILUVIEN Side Effects 
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Intraocular Pressure (IOP) > 30mm Hg 
3 Years All Patients:     14.1% risk 
 18.4 % Iluvien vs 4.3% control 
              4.8% required procedure  
3 Years Chronic DME:   9.4% risk 
 14.8% Iluvien vs 5.4% control  
              5.2% required procedure 
        
Cataract  
34% of patients in trial had already 
undergone cataract surgery 
Approx. 85% of low dose patients 
developed cataract 
New Generation Drug Delivery Technologies 
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300X 
• Fully bio-erodible 
 
• Potential to deliver 
drugs, peptides and 
proteins 
 
• Very promising 
preliminary data 
BioSilicon: A highly porous material 
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1cm3 of bioSilicon™ 
 i.e. sugar cube 
Total surface area 
equivalent  
to 2 tennis courts 
If the columnar pores were  
Stacked the length would  
measure 6 million miles 
BioSilicon Technology 
BioSilicon Technology:  
Stabilization of amorphous forms 
Enhanced dissolution and Bioavailability of 
poorly soluble molecules 
 
Tethadur Systems:   
Protein Adsorption  
Sustained Release Anti-Bodies 
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Drug Loaded BioSilicon 
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BioSilicon Unprocessed API 
API and BioSilicon API in BioSilicon 
Indomethacin in BioSilicon 





























































Stability of Amorphous Indomethacin 





































Time 0 Weeks at 40°C/ 75% RH 
Indomethacin in BioSilicon 





































Time 0 6 month at 40°C/ 75% RH 
Stabilization of Amorophous Form 
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Indomethacin Dissolution 
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Indomethacin Oral Bioavailability 





















BioSilicon™ co-formulation Indocid®  Amorphous control
Tethadur Technology 
Sustained Release of Proteins 
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Tethadur System 
 
 Fully bioerodible 
 Microparticulate (< 10 µm) 
 Nanostructured  



































Equilibrium Concentration (µM) 
60 150 250 500






60 299.2 0.238 
150 257.1 0.107 
250 251.1 0.069 
500 105.8 0.030 
60Å 
250Å 
Effect of Pore Size on Protein Release Rate 
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In-Vitro Release Rate of “real” Protein 
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SUMMARY 
 Nano-structuring  can maintain target 
molecules in amorphous form 
 Effect on release a function of elimination of 
lattice energy versus creation of agent/wall 
interaction 
 Agent/wall interaction adjustable allowing 
release rate to be controlled 
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